Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) EBT Margin (2020 - 2023)

Gain Therapeutics has reported EBT Margin over the past 4 years, most recently at 9279.8% for Q1 2023.

  • Quarterly results put EBT Margin at 9279.8% for Q1 2023, down 201195.0% from a year ago — trailing twelve months through Dec 2023 was 40210.67% (down 4009928.0% YoY), and the annual figure for FY2023 was 40210.67%, down 4009928.0%.
  • EBT Margin for Q1 2023 was 9279.8% at Gain Therapeutics, down from 5337.72% in the prior quarter.
  • Over the last five years, EBT Margin for GANX hit a ceiling of 8411.38% in Q4 2021 and a floor of 46440.84% in Q1 2021.
  • Median EBT Margin over the past 4 years was 8735.52% (2020), compared with a mean of 11679.65%.
  • Biggest five-year swings in EBT Margin: crashed -3770533bps in 2021 and later surged 3917300bps in 2022.
  • Gain Therapeutics' EBT Margin stood at 18131.62% in 2020, then surged by 146bps to 8411.38% in 2021, then plummeted by -163bps to 5337.72% in 2022, then crashed by -74bps to 9279.8% in 2023.
  • The last three reported values for EBT Margin were 9279.8% (Q1 2023), 5337.72% (Q2 2022), and 7267.84% (Q1 2022) per Business Quant data.